Back to HCMView full pipeline
Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
0 competitors in Relapsed/Refractory Follicular Lymphoma With EZH2
View Full LandscapeDrug Information
Target Indication
Relapsed/Refractory Follicular Lymphoma With EZH2
Clinical Trial
NCT05467943Last updated: 12/13/2025
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Drug Science
Mechanism of action & safety profile
Related Pipeline
fruquintinib+sintilimabPhase 3
Advanced Renal Cell Carcinoma
HMPL-306 RegimenPhase 3
Acute Myeloid Leukemia
HMPL-453Phase 3
Advanced Intrahepatic Cholangiocarcinoma
Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and GemcitabinePhase 3
Metastatic Pancreatic Cancer
fruquintinibPhase 3
Advanced Endometrial Cancer
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts